{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:40:15Z","timestamp":1777934415456,"version":"3.51.4"},"reference-count":18,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The immune checkpoint inhibitors (ICIs), which are used to activate the immune system and stimulate anti-tumor activity, are preferred in many cancers. Atezolizumab acts by blocking programmed cell death ligand (PD-L1) and may cause immune hyperstimulation in healthy tissues like other ICIs, resulting in immune-related adverse events (irAEs). Hepatitis, colitis, pneumonitis, hypophysitis, hypothyroidism, rash, musculoskeletal problems are the most common irAEs, and on the other hand, acute kidney injury (AKI) and immune thrombocytopenic purpura (ITP) are infrequent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>We present a case with non-small cell lung cancer (NSCLC) treated with atezolizumab 1200\u2009mg every three weeks for third-line treatment. The patient was admitted with fatigue and back pain. The patient\u2019s complaints started one week after the first dose of atezolizumab. The patient had renal injury and thrombocytopenia and was diagnosed with drug-induced AKI and ITP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management and outcome<\/jats:title>\n                    <jats:p>After platelet replacement, intravenous immunoglobulin (IVIG), and steroid therapy, the patient whose platelet count was normalized and creatinine level regressed was discharged, and routine follow-up continues.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Here, we present a case with NSCLC treated with atezolizumab and with drug-induced ITP and AKI association. Given that atezolizumab and other immune checkpoint inhibitors are being utilized in the treatment of cancers, physicians should be aware of the irAEs, including the AKI and ITP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155220913081","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T21:56:12Z","timestamp":1585778172000},"page":"1791-1794","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":15,"title":["Possible atezolizumab-associated acute kidney injury and immune thrombocytopenia"],"prefix":"10.1177","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6078-8651","authenticated-orcid":false,"given":"Ali","family":"Y\u0131lmaz","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Department of Medical Oncology, Atat\u00fcrk University, Erzurum, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cem","family":"Mirili","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Medical Oncology, Atat\u00fcrk University, Erzurum, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Bilici","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Medical Oncology, Atat\u00fcrk University, Erzurum, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salim Ba\u015fol","family":"Tekin","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Medical Oncology, Atat\u00fcrk University, Erzurum, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,4,1]]},"reference":[{"key":"bibr1-1078155220913081","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"bibr2-1078155220913081","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615"},{"key":"bibr3-1078155220913081","doi-asserted-by":"publisher","DOI":"10.1038\/nature13904"},{"key":"bibr4-1078155220913081","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"bibr5-1078155220913081","doi-asserted-by":"publisher","DOI":"10.1177\/1753465816636557"},{"key":"bibr6-1078155220913081","unstructured":"Cortazar FB, Marrone KA, Troxell ML, et\u00a0al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Leaf Kidney International, 2016, http:\/\/dx.doi.org\/10.1016\/ j.kint.2016.04.008 (accessed 10 March 2020)."},{"key":"bibr7-1078155220913081","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1445952"},{"key":"bibr8-1078155220913081","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0574"},{"key":"bibr9-1078155220913081","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr10-1078155220913081","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1417"},{"key":"bibr11-1078155220913081","first-page":"730","volume":"8","author":"Wang PF","year":"2017","journal-title":"Pharmacol"},{"key":"bibr12-1078155220913081","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k793"},{"key":"bibr13-1078155220913081","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225"},{"key":"bibr14-1078155220913081","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0210-0"},{"key":"bibr15-1078155220913081","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.4049\/jimmunol.148.8.2324","volume":"148","author":"Hagerty DT","year":"1992","journal-title":"J Immunol"},{"key":"bibr16-1078155220913081","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.11.7466"},{"key":"bibr17-1078155220913081","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx693"},{"key":"bibr18-1078155220913081","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30175-3"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220913081","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220913081","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220913081","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:22:46Z","timestamp":1777688566000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220913081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1177\/1078155220913081"],"URL":"https:\/\/doi.org\/10.1177\/1078155220913081","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,1]]}}}